• About
  • Masthead
  • License Content
  • Advertise
  • Press Releases
  • Newsroom
  • RSS/Email List
  • 2MM Podcast
  • Write for us
  • Contact Us
2 Minute Medicine
No Result
View All Result

No products in the cart.

Sign in
SUBSCRIBE
  • About
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
    • Rewinds
    • The Scan
  • EvidencePulse™
  • HypeCheck™
  • AI News
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Tools
    • NPI Registry Lookup
    • RVU Search
    • Physician Pay by Specialty
    • ICD-10 Code Lookup
    • FDA Drug Approvals
    • Drug Safety for Breastfeeding/Pregnancy
    • Clinical Guidelines
    • Medical Calculators
    • ECG Reference
      • QTc Calculator
      • Sgarbossa Criteria
      • ECG Axis Calculator
      • AV Block Helper
  • Rankings
    • Medical School Rankings
    • Residency Rankings
  • Partners
    • License Content
    • Advertise with Us
2 Minute Medicine
  • About
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
    • Rewinds
    • The Scan
  • EvidencePulse™
  • HypeCheck™
  • AI News
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Tools
    • NPI Registry Lookup
    • RVU Search
    • Physician Pay by Specialty
    • ICD-10 Code Lookup
    • FDA Drug Approvals
    • Drug Safety for Breastfeeding/Pregnancy
    • Clinical Guidelines
    • Medical Calculators
    • ECG Reference
      • QTc Calculator
      • Sgarbossa Criteria
      • ECG Axis Calculator
      • AV Block Helper
  • Rankings
    • Medical School Rankings
    • Residency Rankings
  • Partners
    • License Content
    • Advertise with Us
Sign in
SUBSCRIBE
2 Minute Medicine
Sign in
Subscribe
2 Minute MedicineFree on Google PlayGet
✦EvidencePulse™by 2 Minute Medicine3 reportsYou askedtop stroke trials 2026Synthesizing medical evidence...Top 2026 stroke trial results:OCEANIC — ischemic stroke: 6.2% vs 8.4%OPTION* — mRS 0–1: 43.6% vs 34.2%ORIENTAL* — mRS 0–2: 58.6% vs 46.6%*Higher sICH in intervention armsParticipants randomizedNOCEANIC12,327OPTION570ORIENTAL564Ask about guidelines or landmark trials...↑Try EvidencePulse™Ask the evidence. Get the signal.Try it now →
Home All Specialties Chronic Disease

Roflumilast cream superior to vehicle cream in the treatment of plaque psoriasis – the DERMIS-1 and DERMIS-2 trials

byGursharan SohiandYuchen Dai
September 24, 2022
in Chronic Disease, Dermatology
Reading Time: 3 mins read
Share on FacebookShare on TwitterShare on LinkedIn

1. Treatment of plaque psoriasis with roflumilast cream was associated with better clinical outcomes compared to vehicle cream after 8 weeks of treatment.

2. The incidence of serious adverse events was equal in the two treatment groups.

Level of Evidence Rating: 1 (Excellent)

Study Rundown: Roflumilast is a phosphodiesterase inhibitor (PDEi) which can be used in the management of respiratory disease such as chronic obstructive pulmonary disease. Recently, it has also been trialed as a topical formulation in the management of dermatological disease including plaque psoriasis. This study reports the results of two Phase 2b studies (DERMIS-1 and DERMIS-2) assessing roflumilast versus vehicle cream in the management of plaque psoriasis.

Data from 783 individuals was included in this study. In Trial 1 42.4% of the roflumilast-

treated and 6.1% of the vehicle-treated patients achieved the primary outcome at 8 weeks. At the same time point in Trial 2, 37.5% of the roflumilast patients and 6.9% of the vehicle patients had achieved the desired treatment response. Analysis of secondary outcomes demonstrated that roflumilast performed better with regards to achieving treatment response compared to the vehicle cream at all time points. The rate of adverse events in Trial 1 was 25.2% in the roflumilast group and 23.5% of patients in the vehicle group. In Trial 2 the rate of adverse events in the intervention and control groups were 25.9% and 18.4%, respectively. The rate of serious adverse events was 0.7% in all trial groups except for the roflumilast group in Trial 2, who experienced zero adverse events.

RELATED REPORTS

In topline phase 3 results, nomelcitinib improved PASI 90 and PGA 0/1 responses versus placebo in plaque psoriasis

The Scan by 2 Minute Medicine®: The Sound of Music, The Rise of a Promising Alzheimer’s Treatment, Pediatric Liver Transplant, A Heart-shaped Rash

This study by Lebwohl et al summarizes the results of two randomized controlled trials of roflumilast cream versus placebo for the management of plaque psoriasis. The study showed a significant improvement in clinical status following treatment with roflumilast compared to the vehicle cream at all time points, and no difference in the rate of adverse events. The results of this trial are convincing, given the randomized design which does well to account for confounding and the strong treatment effect demonstrated in the roflumilast group. A limitation of the two trials is the lack of follow-up data beyond 8 weeks.

Click here to read this study in JAMA (Journal of the American Medical Association)

Click to read an accompanying editorial in JAMA

Relevant reading: Roflumilast foam 0.3% treatment of seborrheic dermatitis is effective and safe and improves patient quality of life: results from a phase 2 study

FDA approvedFor plaque psoriasis: Icotyde (icotrokinra), Mar 17, 2026→

In Depth [randomized controlled trial]: The results of two trials are reported in this article: Trial 1 was a 12-week trial of 331 patients and Trial 2 was a 52-week trial. Patients were eligible if they were aged 2 years or above and had been diagnosed with plaque psoriasis for at least 6 (adults) or 3 (children) months. The primary outcome was measured by the Investigator Global Assessment of success (IGA) in terms of clearance of the psoriatic plaques. Specifically, treatment success was defined as nearly/all clear, or improvement by at least 2 IGA stages at week 8 of treatment. Patients were randomized in a 2:1 fashion to treatment with either 0.3% roflumilast cream or vehicle cream; randomization was stratified by study site, baseline IGA score and presence of intertriginous lesions. Participants were blinded to the nature of the intervention.

Trial 1 included data from 388 participants and Trial 2 included data from 395 participants. Baseline characteristics and demographic information were balanced between the two groups in each trial. In Trial 1, 42.4% of the roflumilast-treated and 6.1% of the vehicle-treated patients achieved the primary outcome at 8 weeks. The mean difference was 39.6% (95% confidence interval 32.3-46.9%). After 8 weeks in Trial 2, 37.5% of the roflumilast patients and 6.9% of the vehicle patients had achieved the desired treatment response. The mean effect difference was 28.8% (95% confidence interval 20.8-36.9%). The number needed to treat for improvement with roflumilast was 2.8 (2.3-3.4) in Trial 1 and 3.3 (2.6-4.3) in Trial 2. There were no significant differences in rates of adverse events between the two groups.

Image: PD

©2022 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Tags: phosphodiesterase 4 inhibitorplaque psoriasisroflumilast
Previous Post

Factors associated with anticoagulation discontinuation in palliative care patients

Next Post

2 Minute Medicine Rewind September 26, 2022

RelatedReports

Psoriasis collage: an elbow with raised scaly patches, a jar of thick cream, oat stalks and a light therapy panel
2MM Trial Briefs

In topline phase 3 results, nomelcitinib improved PASI 90 and PGA 0/1 responses versus placebo in plaque psoriasis

November 2, 2026
The Scan by 2 Minute Medicine®:  Ultra-Trail du Mont-Blanc, Taylor Swift, NBA rookie Chet Holmgren and Magic Mushrooms!
The Scan by 2 Minute Medicine®

The Scan by 2 Minute Medicine®: The Sound of Music, The Rise of a Promising Alzheimer’s Treatment, Pediatric Liver Transplant, A Heart-shaped Rash

February 20, 2024
Eczema more prevalent among older adults than previously thought
Dermatology

IL-23 inhibitors may have a lower risk of paradoxical eczema in comparison to other biologics

January 26, 2024
Collage on seborrheic dermatitis: an engraved eye and eyebrow with fine flakes, a plain shampoo bottle and yeast cells
Dermatology

Phase 2 Randomized Trial Supports Roflumilast as a Potential Treatment for Seborrheic Dermatitis

June 1, 2023
Next Post
Colchicine may lower the risk of cardiovascular events in patients with coronary disease

2 Minute Medicine Rewind September 26, 2022

Bisphosphonate use and risk of atypical femur fractures

Risk of hip fracture in meat-eaters, pescatarians, and vegetarians

Decreased expression of nasal ACE2 may be correlated with lower prevalence of COVID-19 in children

Regular physical activity may confer protection against adverse COVID-19 outcomes

✦ EvidencePulse™ by 2 Minute Medicine 3 reports You asked top stroke trials 2026 Synthesizing medical evidence... Top 2026 stroke trial results: OCEANIC — ischemic stroke: 6.2% vs 8.4% OPTION* — mRS 0–1: 43.6% vs 34.2% ORIENTAL* — mRS 0–2: 58.6% vs 46.6% *Higher sICH in intervention arms Participants randomizedN OCEANIC 12,327 OPTION 570 ORIENTAL 564 Ask about guidelines or landmark trials... Try EvidencePulse™ Get the signal. Try it now → Physician-trained medical AI by 2 Minute Medicine

2MM+ All Access

Full details →
$4.99 /month

3-day free trial · cancel anytime

  • ✓100+ physician-written reports
  • ✓EvidencePulse™ + HypeCheck™
  • ✓Ad-free reading + newsletters
Start 3-day free trial

Then $4.99/month. Manage renewal in your account.

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Social isolation and loneliness is associated with worse physical and mental health among middle-aged and older adults
  • Gait analysis predicts health, sleep, and medication use across 18 body systems
  • Bariatric surgery associated with lower obesity-related cancer incidence in Nordic cohort
License Content
Terms of Use | Disclaimer
Cookie Policy

Get the app

Read 2 Minute Medicine on iPhone, iPad and Android.

Download on the App StoreGet it on Google Play
QR code for www.2minutemedicine.com/app
On a computer? Scan this with your phone’s camera.
2MM+ All Access Full details →

The medical literature, distilled daily.

Monthly plan selected: $4.99 /month.

$4.99/month

3-day free trial · cancel anytime

Start 3-day free trial

Then $4.99/month. Manage renewal in your account.

Yearly plan selected: $49.90 /year.

$49.90/year

2 months free

Start 3-day free trial

Then $49.90/year.

Membership benefits

  • ✓100+ new physician-written study summaries monthly, 12,000+ searchable
  • ✓AI EvidencePulse™ + HypeCheck™
  • ✓Ad-free reading + newsletters
  • ✓FDA drug approvals + clinical calculators

Already a member? Sign in

  • Get the app
  • About
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
    • Rewinds
    • The Scan
  • EvidencePulse™
  • HypeCheck™
  • AI News
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Tools
    • NPI Registry Lookup
    • RVU Search
    • Physician Pay by Specialty
    • ICD-10 Code Lookup
    • FDA Drug Approvals
    • Drug Safety for Breastfeeding/Pregnancy
    • Clinical Guidelines
    • Medical Calculators
    • ECG Reference
      • QTc Calculator
      • Sgarbossa Criteria
      • ECG Axis Calculator
      • AV Block Helper
  • Rankings
    • Medical School Rankings
    • Residency Rankings
  • Partners
    • License Content
    • Advertise with Us
No Result
View All Result

© 2026 2 Minute Medicine, Inc. - Physician-written medical news.